Condition:  Ovarian Cancer
Interventions:  Drug: Ipatasertib;  Drug: Cobimetinib;  Drug: Trastuzumab Emtansine;  Drug: Atezolizumab;  Drug: Bevacizumab;  Drug: Paclitaxel;  Drug: Giredestrant;  Drug: Abemaciclib;  Drug: Inavolisib;  Drug: Palbociclib;  Drug: Letrozole;  Drug: Olaparib;  Drug: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Sponsors:  Hoffmann-La Roche;  GOG Foundation;  European Network of Gynaecological Oncological Trial Groups (ENGOT)
**RECRUITING NOW**
Interventions:  Drug: Ipatasertib;  Drug: Cobimetinib;  Drug: Trastuzumab Emtansine;  Drug: Atezolizumab;  Drug: Bevacizumab;  Drug: Paclitaxel;  Drug: Giredestrant;  Drug: Abemaciclib;  Drug: Inavolisib;  Drug: Palbociclib;  Drug: Letrozole;  Drug: Olaparib;  Drug: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Sponsors:  Hoffmann-La Roche;  GOG Foundation;  European Network of Gynaecological Oncological Trial Groups (ENGOT)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
